Developments in the drug treatment of schizophrenia.
Despite its efficacy in many cases, the drug treatment of schizophrenia remains problematic. A substantial proportion of patients do not improve, and many others suffer from unpleasant side-effects. In this review, Gavin Reynolds describes the new approaches to antipsychotic drug development that attempt to address these problems, and relates some of these approaches to growing evidence for neuronal pathology in the brain in schizophrenia.
Department of Biomedical Science, University of Sheffield, UK.
G P
GP
Reynolds
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018492:Dopamine Antagonists; D006801:Humans; D009292:Narcotic Antagonists; D011954:Receptors, Dopamine / Q000378:metabolism; D017470:Receptors, Glutamate; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D017480:Receptors, sigma; D012559:Schizophrenia / Q000188:drug therapy*; D012702:Serotonin Antagonists
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D009292:Narcotic Antagonists; D011954:Receptors, Dopamine; D017470:Receptors, Glutamate; D017981:Receptors, Neurotransmitter; D011957:Receptors, Opioid; D011985:Receptors, Serotonin; D017480:Receptors, sigma; D012702:Serotonin Antagonists